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Introduction: The aim of this study was to determine if there are differences between patients with pre-existing left
ventricular dysfunction and those with normal antecedent left ventricular function during a sepsis episode in terms
of in-hospital mortality and mortality risk factors when treated in accordance with a sepsis treatment algorithm.
Methods: We performed a retrospective case-control analysis of patients selected from a quality improvement
database of 1,717 patients hospitalized with sepsis between 1 January 2005 and 30 June 2010. In this study, 197
patients with pre-existing left ventricular systolic dysfunction and sepsis were compared to 197 case-matched
patients with normal prior cardiac function and sepsis.
Results: In-hospital mortality rates (P = 0.117) and intubation rates at 24 hours (P = 0.687) were not significantly different
between cases and controls. There was no correlation between the amount of intravenous fluid administered over the
first 24 hours and the PaO2/FiO2 ratio at 24 hours in either cases or controls (r
2 = 0.019 and r2 = 0.001, respectively).
Mortality risk factors for cases included intubation status (P = 0.016, OR = 0.356 for no intubation), compliance with a
sepsis bundle (P = 0.008, OR = 3.516 for failed compliance), a source of infection other than the lung (P = 0.019,
OR = 2.782), and the initial mixed venous oxygen saturation (P = 0.004, OR = 0.997). Risk factors for controls were the initial
platelet count (P = 0.028, OR = 0.997) and the serum lactate level (P = 0.048, OR = 1.104). Patients with pre-existing left
ventricular dysfunction who died had a lower initial mean mixed venous oxygen saturation than those who survived
(61 ± 18% versus 70 ± 16%, P = 0.002).
Conclusions: Clinical outcomes were not different between septic patients with pre-existing left ventricular
dysfunction and those with no cardiac disease. There was no correlation between fluid administration and oxygenation
at 24 hours in either cohort. The mortality risk factor profile of patients with pre-existing left ventricular dysfunction was
different when compared with control patients, and may be related to oxygen delivery determinants.Introduction
Severe sepsis and septic shock represent serious medical
conditions with high morbidity and mortality rates. Sepsis
is a leading cause of death [1,2], and frequently causes
end-organ damage [3], as well as cognitive and physical
disability in survivors [4]. In the United States, over $14
billion were spent on hospitalizations for sepsis in 2008
alone [5]. The hospitalization rate for sepsis has more than
doubled between 2000 and 2008, with a rate of 24 per
10,000 persons in 2008 [2]. Patients hospitalized with
sepsis have a length of stay nearly twice that of other* Correspondence: douelle1@hfhs.org
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distribution, and reproduction in any mediumpatients and are eight times more likely to die than other
patients [2,6]. Early aggressive treatment for sepsis increases
the chances for survival [7]. Tenets of aggressive treatment
include early antibiotic therapy [8] and aggressive resuscita-
tive strategies to achieve monitored clinical goals [9].
Patients with sepsis are a heterogeneous group with
various predisposing features and sources of infection.
Patients who are critically ill from all causes have a
higher mortality when they have cardiac dysfunction
[10]. Sepsis may be associated with concurrent reversible
left ventricular dysfunction (LVD) [11] that some authors
have attributed to circulating factors [2,12]. Patients with
LVD that occurs during sepsis may have a worse prognosis
than patients who do not have this condition [12,13].entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patients [14], which may complicate the management of
sepsis. However, the outcomes for septic patients who
have pre-existing LVD have not been carefully studied.
Early sepsis management requires aggressive fluid
resuscitation to defined clinical endpoints, whereas it may
be necessary to be more circumspect in the administration
of fluids in later phases of sepsis [15]. The presence of
LVD in critically ill septic patients complicates this
strategy and leads to concerns about the development of
pulmonary edema and respiratory failure from excessive
fluid resuscitation. Alterations in the cardiac compliance
in patients with LVD may diminish the utility of the
central venous pressure as a preload assessment tool
[16]. Both the mixed venous oxygen saturation (ScVO2)
and the serum lactate level may be affected by the presence
of LVD as well as sepsis, potentially confounding their
utility in patients with both disorders [17-19]. More
data are needed to guide clinicians in the management
of these difficult patients.
Our institution has maintained an extensive database
since 2005 for all hospitalized patients treated for sepsis.
We selected a population of patients with both acute
sepsis and prior evidence of LVD for this study. In order
to determine if differences exist between septic patients
with pre-existing LVD and those without, we selected
case-matched control patients with normal pre-sepsis LV
function for comparison purposes. We chose to analyze
clinical parameters of both case and control patients in
order to identify risk factors for in-hospital mortality.
The identification of differences between septic patients
with and without pre-existing LVD, and the ascertainment
of sepsis mortality risk factors in each group, may lead
to the refinement of management algorithms in the
subpopulation of patients with pre-existing LVD.
Materials and methods
Study design and enrollment
All patients at our institution who developed sepsis after
January 2005 had medical data entered into an insti-
tutional sepsis quality improvement database. Patients
admitted to the Emergency Department, hospital wards
or intensive care units with a diagnosis of sepsis, as well
as those who developed sepsis during the course of their
hospital stay for another diagnosis, were included in
the database. We retrospectively reviewed data collected
between 1 January 2005 and 30 June 2010. We add-
itionally examined data from the institutional electronic
medical record (EMR) of all patients enrolled in the sepsis
database. The study was performed at a quaternary health
care system located in the midwestern United States. The
study protocol was ethically reviewed and approved by
the Henry Ford Health Systems Institutional Review
Board (IRB project number 6237; Henry Ford HealthSystems Institutional Review Board). The need for informed
consent was waived by the Henry Ford Health Systems
Review Board because the study was an observational
non-interventional retrospective study using a database
where patient identification information had been removed.
Case subjects were identified as those patients entered
into the sepsis database that had an echocardiogram
performed and entered into the EMR prior to (but not
more than two years before) the incidence of sepsis
with a reported left ventricular ejection fraction (LVEF) of
50% or less. When patients had multiple echocardiograms
reported in the EMR prior to the sepsis event, we used
the results from the echocardiogram performed most
proximate to the event. Each case subject had the diagnosis
of sepsis confirmed by retrospective review of the EMR. If
a potential case subject had multiple admissions entered
into the database, only the first admission was considered
for study purposes. Potential case subjects were excluded
if they were receiving renal replacement therapy prior to
the sepsis event. These patients were excluded because
the physiologic factors associated with end-stage renal
disease and its management could confound the analysis
of the effects of left ventricular dysfunction in patients
with sepsis. Patients with any degree of renal insuffi-
ciency not requiring renal replacement therapy (including
patients who had received a kidney transplant), or who
developed a need for renal replacement therapy while
being treated for sepsis, were included in the study if
they met enrollment criteria.
Control subjects were chosen from the database for
each case subject in a 1:1 ratio by selecting from age- and
gender-matched patients with an LVEF greater than 50%
by echocardiogram (not concurrent but within two years
of the sepsis event). The potential control subject with
a date of birth closest to the case subject was selected.
Potential control subjects were excluded if they had cardiac
wall motion abnormalities, valvular cardiac abnormalities,
significant evidence of diastolic dysfunction on echocar-
diogram, or had any evidence of an acute cardiac ischemic
syndrome during their hospitalization for sepsis. Control
subjects were otherwise required to meet the same inclu-
sion criteria as case subjects. The information for each
study subject was entered into a research database without
patient identifiers for analysis.
Definitions
“Sepsis” was defined as being present if a patient mani-
fested at least two of four systemic inflammatory response
syndrome criteria and had documented evidence of in-
fection. “LVEF” was defined as the estimated fractional
diminution in size of the left ventricular cavity during
systole as reported in standard echocardiographic inter-
pretations. When a range was provided in a report for
LVEF, the midpoint of that range was chosen as the
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the algorithm used for sepsis management described by
Rivers and co-workers [9]. “Compliance with the sepsis
bundle” was defined as being present when the patient
was treated completely in accordance with the sepsis bun-
dle. The patient was not compliant with the sepsis bundle
if any parameter of the sepsis bundle was not met. “Time
0” was defined as the point in time when the sepsis bundle
was initiated for each study subject. “Intubation” was
defined as endotracheal intubation and mechanical venti-
lation within 24 hours of Time 0.
Statistical analysis
We performed all statistical analysis using SPSS software
version 18 with a logistical regression add-on package ver-
sion 20 (International Business Machines, Armonk, New
York, United States of America) and considered P <0.05
to be statistically significant unless otherwise specified.
We used chi-squared tests, two-sample t tests, or Mann-
Whitney U tests as appropriate for univariable analysis.
Adjustments were not made for multiple comparisons.
For both case and control subjects, we analyzed the re-
lationship between the dependent variable PaO2/FiO2 at
24 hours and the total intravenous fluid volume admin-
istered over 24 hours using linear regression analysis.
Results are displayed as scatter plots and the goodness
of fit is indicated by r2.
Cases and controls were matched for age and gender.
We used multivariable logistic regression analysis with
mortality as the dependent variable to additionally con-
trol for the effects of ScVO2, hematocrit, lactate levels
and intubation status on the association of mortality be-
tween cases and controls.
We developed a model to identify risk factors for mor-
tality by multivariable logistic regression analysis in both
the case and control subject populations. Potential risk
factors were identified from a univariable analysis of each
of the available variables using mortality as the dependent
variable. Variables were selected for analysis if they were
significantly associated with mortality (P <0.1) and if at
least 80% of the case and control subjects had data
available for the variable. A correlation matrix was con-
structed for the continuous independent variables in the
case and control subject populations and the variables
were examined for collinearity by Pearson’s correlation.
Results
Clinical data were collected in a quality improvement
database at our institution for 1,717 hospitalized patient
episodes with a diagnosis of sepsis between 1 January 2005
and 30 June 2010. Of these patients, 510 died during
their hospital stay, while 1,207 survived until discharge,
for an in-hospital all-cause mortality rate of 29.7%. We
identified 197 study subjects who met inclusion criteriaand had both sepsis and pre-existing LVD. We chose 197
control subjects with normal left ventricular function
from the quality improvement database matched to cases
according to age and gender. Comparisons between the
mean values for various clinical variables for cases and
controls are presented in Table 1. Comparisons of clinical
outcomes for cases and controls are presented in Table 2.
When controlled for ScVO2, hematocrit, lactate levels
and intubation status by multivariable logistic regression
analysis using mortality as the dependent variable, the
mortality risk between cases and controls was not differ-
ent (P = 0.183, OR = 1.41). The other risk factors studied,
ScVO2 (P = 0.005, OR = 0.998), intubation (P = 0.000,
OR = 2.56), hematocrit (P = 0.012, OR = 0.996) and initial
lactate level (P = 0.037, OR = 1.078) were all significantly
associated with mortality.
In order to study the effect of the administration of
intravenous fluid volume on respiratory gas exchange, we
examined the relationship between the total intravenous
fluid volume administered during the first 24 hours of
patient admission with the ratio of the partial pressure
of oxygen to the fraction of inspired oxygen (PO2/FiO2)
obtained at 24 hours by linear regression analysis in
both cases and controls. Data for the volume of fluid
administered were available for most patients (n = 190
for cases; n = 192 for controls), but the data availability
for the PO2/FiO2 at 24 hours was more limited (n = 108
for cases; n = 115 for controls). We found no relationship
between intravenous fluid volume and the PO2/FiO2 at
24 hours in either cases or controls (r2 = 0.019 for cases,
r2 = 0.001 for controls; Figures 1 and 2).
We examined the population of patients with pre-
existing LVD to determine if there were differences
between those subjects with more severe LVD compared
to those subjects with less severe dysfunction other than
the reduction in LVEF. There were 81 patients with an
LVEF of less than 35%, compared to 116 patients with
an LVEF greater than or equal to 35% but less than
50%. Patients with an LVEF less than 35% received less
intravenous fluid during their resuscitation than did
patients with a higher LVEF (3.40+/-2.07 L compared with
4.42+/-3.09 L, P = 0.012). However, mortality rate (27%
versus 35%, P >0.05), intubation rate (47% versus 43%,
P >0.05), use of vasopressors (46% versus 44%, P >0.05),
Acute Physiology and Chronic Health Evaluation II (APA-
CHE II) score (20+/-7 versus 19+/-6, P = 0.285), ScVO2
(67.9+/-16.0% versus 66.0+/-17.1%, P = 0.472), and initial
lactate levels (3.8+/-3.7 mmol/L versus 3.1+/-2.5 mmol/L,
P = 0.121) were not statistically different between patients
with an LVEF of less than 35% and those with an LVEF
between 35% and 50%.
We studied both the case and the control populations
to determine the risk factors for mortality in each group.
We applied univariable analysis of 25 potential risk factors
Table 1 Comparisons of clinical variables between cases and controls
Variable Cases (n) Controls (n) P
Age (years) 68 +/- 16 (197) 67 +/- 16 (197) 0.935b
Male gender 129 (197) 129 (197) 1.000a
LVEF (%) 35 +/- 12 (197) 60 +/- 5 (197) <0.001b
APACHE II 20 +/- 7 (194) 19 +/- 8 (191) 0.603b
Initial CVP (cm H2O) 9 +/- 8 (128) 8 +/- 7 (120) 0.334
b
ScVO2 (%) 67 +/- 17 (166) 71 +/- 16 (166) 0.009
b
Lung Infection 64 (197) 54 (197) 0.322a
Sepsis bundle compliant 61 (197) 69 (197) 0.453a
MAP <65 mm Hg 116 (197) 114 (197) 0.919a
Initial temperature (°C) 36.9 +/- 1.6 (196) 37.0 +/- 1.5 (195) 0.714b
Temperature at 24 hours (°C) 37.2 +/- 2.0 (197) 37.3 +/- 2.0 (197) 0.471b
Initial heart rate (min−1) 104 +/- 27 (197) 108 +/- 24 (197) 0.074b
Heart rate at 24 hours (min−1) 115 +/- 32 (197) 117 +/- 29 (197) 0.360b
Initial respiratory rate (min−1) 24 +/- 9 (197) 24 +/- 9 (197) 0.558b
Respiratory rate at 24 hours (min−1) 29 +/- 9 (197) 30 +/- 9 (197) 0.435b
Initial MAP (mm Hg) 74 +/- 22 (197) 76 +/- 23 (197) 0.502b
MAP at 24 hours (mm Hg) 58 +/- 19 (197) 60 +/- 21 (197) 0.226b
Initial pH 7.35 +/- 0.12 (176) 7.35 +/- 0.13 (175) 0.994b
pH at 24 hours 7.31 +/- 0.13 (112) 7.29 +/- 0.15 (107) 0.302b
Initial PO2/FiO2 259 +/- 130 (161) 266 +/- 139 (166) 0.630
b
PO2/FiO2 at 24 hours 265 +/- 113 (108) 268 +/- 126 (115) 0.846
b
Initial sodium (mg/dL) 139 +/- 7 (196) 139 +/- 12 (197) 0.730b
Initial creatinine (mg/dL) 3.04 +/- 2.72 (195) 2.73 +/- 3.28 (197) 0.115c
Initial hematocrit (%) 31.6 +/- 6.6 (197) 33.1 +/- 8.1 (197) 0.046b
Initial WBC (x103 ul) 15.1 +/- 9.7 (196) 16.4 +/- 15.6 (197) 0.294b
Initial platelet count (x103 ul) 234 +/- 138 (195) 231 +/- 153 (196) 0.844b
Initial lactate (mmol/L) 3.4 +/- 3.0 (196) 4.1 +/- 3.5 (195) 0.019c
Initial glucose (mg/dL) 136 +/- 98 (197) 136 +/- 52 (197) 0.960b
Initial 24-hour fluid volume (ml) 4,005 +/- 2,763 (190) 4,378 +/- 3,040 (192) 0.321c
Receipt of vasoactive agents 88 (197) 79 (197) 0.415a
Significance, P <0.05; aChi-square test; bStudent’s t-test; cMann-Whitney U test. APACHE II, Acute Physiology and Chronic Health Evaluation II; CVP, central venous
pressure; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; PO2/FiO2, partial pressure of oxygen to the fraction of inspired oxygen; ScVO2, mixed
venous oxygen saturation; WBC, white blood count.
Table 2 Comparison of clinical outcomes between cases
and controls
Variable Cases (n) Controls (n) P
MAP >65 mm Hg following
fluid resuscitation
101 (197) 114 (197) 0.225
MAP >65 mm Hg following receipt
of vasoactive agents for hypotension
74 (85) 64 (75) 0.532
Initiation of dialysis 2 (197) 1 (197) 1.000
Intubated 93 (197) 98 (197) 0.687
Mortality 63 (197) 48 (197) 0.117
Chi-square test used for dichotomous variables. MAP, mean arterial pressure.
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and control groups. Results are presented in Table 3.
Significant correlations by Pearson’s correlation were
demonstrated in both populations between the APACHE
II score and the lactate level (P = 0.001). We chose to
exclude APACHE II from the multivariable model. We
also found a significant correlation between the hematocrit
and respiratory rate in the case but not the control subjects
(P = 0.003 for the cases, P = 0.210 for the controls). We
chose to exclude respiratory rate from the model as well.
The model used for the multivariable logistic regression
analysis, with mortality as the dependent variable, and
which was applied to the case and control population
Figure 1 Intravenous fluid volume over the initial 24 hours versus PO2/FiO2 at 24 hours for cases. r2 = 0.019.
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status, ScVO2, initial hematocrit, initial platelet count,
compliance with a sepsis bundle, lung infection, serum
lactate level and the use of vasoactive agents to augment
blood pressure. The results of this analysis are presented
in Table 4. Risk factors for mortality were different
between cases and controls. Significant risk factors for
mortality among patients with pre-existing left ventricular
dysfunction included the ScVO2, compliance with a sepsisFigure 2 Intravenous fluid volume over the initial 24 hours versus POalgorithm, intubation status and a source of infection
other than the lung. Significant risk factors for mortality
among patients with pre-existing normal left ventricular
function included the initial platelet count and the ini-
tial lactate level. While the ScVO2 was similar between
survivors and non-survivors among control patients,
the ScVO2 was significantly lower among non-surviving
patients with pre-existing LVD compared with surviving
patients (Table 5).2/FiO2 at 24 hours for controls. r
2 = 0.001.
Table 3 Risk factors for mortality among cases and
controls by univariable analysis
Risk factors P, cases (n) P, controls (n)
Age 0.122 (197) 0.199 (197)
Initial CVP 0.232 (128) 0.731 (120)
Initial temperature 0.210 (196) 0.243 (195)
Initial heart rate 0.792 (197) 0.885 (197)
Initial respiratory rate 0.626 (197) 0.01 (197)*
Initial MAP 0.792 (197) 0.636 (197)
Initial PO2/FiO2 0.254 (161) 0.267 (166)
PO2/FiO2 at 24 hours 0.155 (108) 0.013 (115)
*
Initial pH 0.374 (176) 0.432 (175)
pH at 24 hours 0.001 (112)* 0.028 (107)*
Initial creatinine 0.166 (195) 0.466 (197)
Initial hematocrit 0.074 (197)* 0.071 (197)*
Initial WBC 0.619 (196) 0.672 (197)
Initial platelet 0.974 (195) 0.055 (196)*
APACHE II 0.028 (194)* 0.007 (191)*
Initial lactate 0.008 (196)* 0.019 (195)*
24-hour fluid volume 0.576 190) 0.747 (192)
ScVO2 0.002 (166)
* 0.882 (168)
Glucose level 0.717 (197) 0.136 (197)
No vasoactive drug use 0.016 (197)# 0.009 (197)#
No Intubation 0.001(197)# 0.007 (197)#
LVEF 0.236 (197) 0.319 (197)
Fail bundle compliance 0.002 (197)# 0.328 (197)
Gender 0.811 (197) 0.880 (197)
Source other than lung 0.006 (197)# 0.754 (197)
Student’s t-test* and Chi Square#; P <0.1 significant. APACHE II, Acute Physiology
and Chronic Health Evaluation II; CVP, central venous pressure; LVEF, left
ventricular ejection fraction; MAP, mean arterial pressure; PO2/FiO2, partial
pressure of oxygen to the fraction of inspired oxygen; ScVO2, mixed venous
oxygen saturation; WBC, white blood count.
Table 4 Risk factors for mortality among cases and controls b
Risk factors P, cases Odds ratio
No intubation 0.016* 0.356
Initial hematocrit 0.148 0.996
Initial platelet 0.700 0.999
Fail bundle compliance 0.008* 3.516
Source other than lung 0.019* 2.782
Initial lactate 0.490 1.040
No vasopressors 0.641 1.228
ScVO2 0.004* 0.997
P <0.05 is significant*. ScVO2, mixed venous oxygen saturation.
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To our knowledge, this is the first study to compare
patients with sepsis and pre-existing LVD to patients with
sepsis with no significant pre-existing cardiac abnormalities.
We found that septic patients with pre-existing LVD
differed only modestly from patients with preserved left
ventricular function at our institution. Both populations
had similar degrees of severity of illness, as assessed by
the APACHE II score. Although patients with pre-existing
LVD had significantly lower ScVO2 values, hematocrit
levels and initial lactate levels than did patients with
normal pre-sepsis ventricular function, other demographic
and laboratory determinants were similar. Important
clinical outcomes, such as in-hospital mortality and intub-
ation rates, were not significantly different between the
two groups of patients, though there was a trend towards
increased mortality in the patients with pre-existing LVD.
Fluid management in critically ill patients with sepsis
is complex, in part because the clinical endpoints for
fluid administration change during the course of the
septic episode. Initially, there is a general consensus that
fluid administration should be liberal and aggressive
[5,9]. Clinical management during the initial 24 hours of
therapy emphasize the use of resuscitation goals that
implicate sufficient tissue delivery of oxygen and include
not only traditional hemodynamic measurements and urine
output but also variables related to oxygen delivery and
consumption, such as hemoglobin and mixed venous
oxygen saturation. Subsequently, however, patient out-
comes are improved in critically ill septic patients by
observing conservative fluid management strategies
[20]. The supporting rationale for the application of
conservative fluid management strategies during the late
stages of sepsis stem from observations of improved
patient outcomes from the use of such strategies for
the treatment of acute lung injury [21,22]. Complex
patients with both pre-existing LVD and sepsis might
be perceived as being more susceptible than other septic
patients to developing respiratory complications from
aggressive initial fluid resuscitation because pulmonary
edema is a component of the congestive heart failurey multivariable logistic regression analysis









Table 5 Comparison of initial mean ScVO2 between
survivors and non-survivors, cases and controls
Group n ScVO2 (%) P
Non-survivors, cases 57 61+/-17
Survivors, cases 109 70+/-16 0.002a
Non-survivors, controls 44 71+/-15
Survivors, controls 124 72+/-16 0.882b
aComparison of means by Student’s t-test, non-survivors and survivors, cases.
bComparison of means by Student’s t-test, non-survivors and survivors, controls.
ScVO2, mixed venous oxygen saturation.
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did not have a different severity of illness nor different
outcomes than patients with LVD but with higher LVEF,
they did receive statistically less intravenous fluid during
this resuscitation. We speculate that this may reflect
practice patterns directed by the assumption just noted.
We observed that patients with both sepsis and pre-
existing LVD were no more likely to be intubated and
require mechanical ventilation than case-matched controls,
although the need for intubation was a mortality risk factor
in these patients. Additionally, we found no correlation
between the amount of resuscitative fluid administered
over the first 24 hours and oxygenation in that group of
cases and controls for whom data were available. We
suggest that patients with sepsis and pre-existing LVD may
be no more likely than other patients to develop respiratory
compromise from goal-directed volume resuscitation in
early sepsis.
Studies involving animal models over 40 years ago
demonstrated that serum lactate levels were elevated
when tissue oxygenation was decreased by experimental
manipulation of the determinants of oxygen delivery
[23,24]. Increased lactate levels have been demonstrated
to be associated with poor outcomes in critically ill
patients [25], patients with circulatory shock [26], and
patients with severe sepsis [27]. Production of lactate
appears to be increased both in patients with circulatory
shock and sepsis, though the putative mechanisms may be
different: in circulatory shock mechanisms implicating
oxygen delivery play an important role, whereas in sepsis
constitutive cellular mechanisms of lactate production are
prominent [28]. While there are some data that suggest
that lactate clearance may be preserved in circulatory
shock [29], lactate clearance seems to be diminished in
some patients with sepsis [30]. We observed that the
mean initial lactate level for patients who had sepsis and
pre-existing LVD was less than that of the control group
in our study, though the mean lactate levels for both
groups were elevated compared to normal values. Initial
lactate levels were closely associated with mortality in our
septic control patients, but not in our septic patients
with pre-existing LVD. The reasons for these findings
are not clear, but may be related to the complexinteraction of multiple factors effecting lactate metabol-
ism in patients with multi-system disease. We suggest
that initial serum lactate levels may be less important a
predictor of outcome in septic patients with pre-existing
LVD than they are in other septic patients.
Kasnitz and co-workers studied the relationship between
ScVO2 and lactate levels in patients with cardiopulmonary
disease, noting that ScVO2 levels were decreased in such
patients and associated with increased lactate levels and
mortality [17]. The presumed mechanism for this pheno-
menon is that diminished cardiac output leads to
decreased oxygen delivery to tissues, increased oxygen
extraction and, therefore, diminished oxygen saturation
in blood returning to the heart [31]. In a large cohort
of patients undergoing coronary artery bypass graft
surgery, a threshold value for ScVO2 less than 60.1% was
identified below which mortality was increased [32]. In
contrast to the findings in patients with cardiogenic shock,
early work suggested that ScVO2 was normal or increased
in patients with septic shock [33]. Mechanistically, it has
been suggested that this phenomenon occurs because of
decreased oxygen extraction and utilization. Krafft and
co-workers provided evidence supporting this hypothesis
in general, but suggested that short-term decrements in
ScVO2 might be associated with adverse clinical outcomes
[34]. More recently, Rivers and associates demonstrated
that a strategy that, in part, targets augmenting ScVO2 in
septic patients leads to improved clinical outcomes [9].
However, the control group in the latter study had a mean
ScVO2 of 49%, which is different from that expected from
prior work. Concerns have been raised about the ability
to generalize the findings of Rivers et al. given that most
septic populations have ScVO2 levels in the normal or
supranormal range [35].
We found that patients with pre-existing LVD and
sepsis had a lower mean initial ScVO2 than a control
group of septic patients, a finding which is supported by
previous work [36]. Patients with pre-existing LVD in
our study who died had a significantly lower ScVO2 than
survivors, and low ScVO2 was an independent risk factor
for mortality. These findings were not observed in the
control cohort. The additional observation that failure
to comply with a protocol targeted to improve oxygen
delivery variables was an independent risk factor for
mortality in cases, but not controls, suggests to us that
patients with pre-existing LVD may have a different
physiological response profile during sepsis than other
septic patients. We postulate that sepsis is a heterogeneous
disorder, and management strategies that target oxygen
delivery variables may be particularly appropriate for
patients with pre-existing LVD.
Our work suffers from a number of important limita-
tions. This study is from a single center, which may limit
the applicability of the results. We retrospectively reviewed
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that unappreciated confounding variables may be present.
We did not assess left ventricular function systematically
during the sepsis event in any patients, leading to the
possibility that controls or cases may have had unrecog-
nized synchronous LVD. The number of patients included
in our study was relatively small, limiting the strength of
our conclusions. Larger, prospective studies will need to be
performed to confirm our findings.
Conclusions
This single center retrospective study demonstrates that
patients with sepsis and pre-existing LVD may have similar
outcomes when compared to patients with sepsis with-
out pre-existing LVD. No correlation was demonstrated
between the amount of intravenous fluid administered
over the first 24 hours and oxygenation at 24 hours in
septic patients either with or without pre-existing LVD.
Mortality risk factors for patients with pre-existing
LVD and sepsis included a low ScVO2, failure to comply
with a sepsis bundle of therapies, intubation status, and a
source of infection other than the lung, whereas mortality
risk factors for septic patients with no previous evidence
of cardiac disease included increased lactate levels and
a low platelet count. Further study will be needed to
determine if improvement of oxygen delivery during
sepsis is more important in ameliorating outcome in
patients with pre-existing LVD compared to those without.
Key messages
 Patients with sepsis and pre-existing left ventricular
dysfunction have similar outcomes when compared
to patients with sepsis with normal pre-existing left
ventricular function.
 Patients with pre-existing left ventricular dysfunction
who suffer from sepsis may be no more likely than
patients with normal left ventricular function and
sepsis to develop respiratory compromise when
treated aggressively with intravenous fluids.
 Patients with pre-existing left ventricular dysfunction
who develop sepsis have different mortality risk factors
than other patients. Mortality risk factors are related to
oxygen delivery variables in these patients.
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